DRAPER, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), a leader in health savings accounts (HSAs) and consumer-directed benefits, is proud to announce Chief Marketing Officer Tia Padia has been recognized with the MarCom Visionary CMO Award for her innovative leadership in the category of Individual’s Body of Work.
This award recognizes Padia’s creative vision to develop the HealthEquity Immersion Experience — a project that showcases HealthEquity’s deep understanding of the client and member benefits journey through an interactive, immersive event.
“This award goes beyond individual recognition, it’s a reflection of the tremendous commitment we have at HealthEquity to understand our customers and use what we learn to empower them,” said Senior Vice President and Chief Marketing Officer, Tia Padia. “Every teammate plays a role in delivering remarkable experiences and I’m deeply honored to represent this work through the Immersion Experience exhibit and now with this award.”
The MarCom Visionary CMO Award recognizes marketing leaders who exemplify creativity, vision, and a commitment to make an impact in the marketing and communications fields. The accolade highlights how Padia successfully blended data-driven insights with empathy and creativity to demonstrate the company’s focus on every aspect of its customers’ benefits journey.
The Innovative Immersion Experience
The HealthEquity Immersion Experience debuted in early 2024 and was guided by three core principles: innovation with purpose, interaction and immersion, and strategic alignment to the HealthEquity mission to save and improve lives by empowering healthcare consumers. Through this event, Padia and her team addressed the challenge of creating a meaningful and interactive experience that brought the HealthEquity client and member journeys to life. Utilizing a combination of virtual and artificial reality technologies, the team thoughtfully crafted personas, and physical elements, where participants were able to step into real-world scenarios, witnessing firsthand the value HealthEquity provides to those managing healthcare expenses.
Key highlights of the experience included:
“The Immersion Experience offers an incredible glimpse into how we’re truly here for our clients,” said HealthEquity CEO, Jon Kessler. “Every product, every service we develop is guided by one core question: how can we better support our members, clients, and partners throughout their benefits journey? We’re continually learning and evolving, always striving to put our clients’ experience at the heart of everything we do.”
Check out the HealthEquity online Immersive Experience by visiting https://info.healthequity.com/benefits-innovation.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 16 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers. With a commitment to saving and improving lives, HealthEquity empowers individuals to take control of their healthcare journey through cutting-edge solutions, innovation, and a relentless focus on well-being. Learn more about HealthEquity’s “Purple service” and our approach to consumer-driven benefits at www.healthequity.com.
Media Contact:
Amy Cerny
Director of Corporate Communications
801-508-3237
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$91.54 |
Daily Change: | 0.45 0.49 |
Daily Volume: | 920,155 |
Market Cap: | US$7.930B |
November 12, 2024 October 15, 2024 September 03, 2024 September 03, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB